grant
The Impact of the Herpes Zoster Vaccine on Herpes Zoster Ophthalmicus
Organization UNIVERSITY OF CALIFORNIA, SAN FRANCISCOLocation SAN FRANCISCO, UNITED STATESPosted 1 Jan 2018Deadline 31 May 2028
NIHUS FederalResearch GrantFY202521+ years oldAcademyAddressAdultAdult HumanAffectAgeAge YearsAmericanAreaAwardBenefits and RisksBlindnessBooster ImmunizationCOVID crisisCOVID epidemicCOVID pandemicCOVID-19COVID-19 crisisCOVID-19 epidemicCOVID-19 eraCOVID-19 global health crisisCOVID-19 global pandemicCOVID-19 health crisisCOVID-19 pandemicCOVID-19 periodCOVID-19 public health crisisCOVID-19 yearsCV-19CaliforniaClinicalClinical TrialsCorneaCoronavirus Infectious Disease 2019CounselingDataData BasesData SourcesDatabasesDevelopmentDoseEconomic IncomeEconomical IncomeEffectivenessElectronic Health RecordEligibilityEligibility DeterminationEpidemiologyEthnic OriginEthnicityEventEvidence based practice guidelinesExclusionEyeEyeballFDA approvedFutureGenderGeneral PopulationGeneral PracticesGeneral PublicGrantHealth CareHerpes ZosterHerpes Zoster OphthalmicusHerpes zoster diseaseHistoryImmunocompromisedImmunocompromised HostImmunocompromised PatientImmunosuppressed HostIncidenceIncomeIndividualInterventionKnowledgeLicensureMethodsMonitorMorbidityMorbidity - disease rateObservation researchObservation studyObservational StudyObservational researchOcular Herpes ZosterOphthalmologyPatientsPhiladelphiaPoliciesPopulationProtocol ScreeningPublic HealthPublishingRaceRacesRecombinantsRecommendationRecording of previous eventsRecurrenceRecurrentRegistriesRelative RisksResearchRiskRisk AssessmentSARS-CoV-2 epidemicSARS-CoV-2 global health crisisSARS-CoV-2 global pandemicSARS-CoV-2 pandemicSARS-coronavirus-2 epidemicSARS-coronavirus-2 pandemicSafetySecondary ImmunizationSevere Acute Respiratory Syndrome CoV 2 epidemicSevere Acute Respiratory Syndrome CoV 2 pandemicSevere acute respiratory syndrome coronavirus 2 epidemicSevere acute respiratory syndrome coronavirus 2 pandemicShinglesSightSpecialistSubgroupSurvey InstrumentSurveysUncertaintyUnited StatesUniversitiesVaccinationVaccinesVeterans Health AdministrationVeterans Health AffairsVisionWeighing patientZonaZosterZoster Vaccineaccept vaccinationaccept vaccineadulthoodage groupaged groupaged groupsaged individualaged individualsaged peopleaged personaged personsaged populationaged populationsagesaging populationbooster vaccinationburden of diseaseburden of illnessclinical carecornealcoronavirus disease 2019coronavirus disease 2019 crisiscoronavirus disease 2019 epidemiccoronavirus disease 2019 global health crisiscoronavirus disease 2019 global pandemiccoronavirus disease 2019 health crisiscoronavirus disease 2019 pandemiccoronavirus disease 2019 public health crisiscoronavirus disease crisiscoronavirus disease epidemiccoronavirus disease pandemiccoronavirus disease-19coronavirus disease-19 global pandemiccoronavirus disease-19 pandemiccoronavirus infectious disease-19data basedata warehousedevelopmentaldisease burdendoubtefficacy trialelectronic health care recordelectronic health medical recordelectronic health plan recordelectronic health registryelectronic medical health recordepidemiologicepidemiologicalevidence based guidelinesevidence based recommendationshealth dataherpes zonahigh riskhistoriesimmunosuppressed patientincomesinsightinsurance claimsmid lifemid-lifemiddle agemiddle agedmidlifepatient populationpolicy recommendationpopulation agingpreventpreventingracialracial backgroundracial originreal world evidencerecommendation for policyresidenceresidential buildingresidential sitesevere acute respiratory syndrome coronavirus 2 global health crisissevere acute respiratory syndrome coronavirus 2 global pandemicsocial health determinantsuptakevaccination acceptabilityvaccination acceptancevaccination confidencevaccination uptakevaccination willingnessvaccine acceptabilityvaccine acceptancevaccine confidencevaccine effectivenessvaccine efficacyvaccine safetyvaccine uptakevaccine willingnessvision lossvisual functionvisual loss
Description preview
PROJECT SUMMARY/ABSTRACT
Herpes zoster (HZ, or shingles) is a major cause of morbidity, affecting one in three Americans during their
lifetime. HZ can be particularly devastating when it involves the eye (herpes zoster ophthalmicus, HZO) and can
result in permanent vision loss. The FDA approved a highly effective HZ vaccine (Shingrix, recombinant…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click